Core Viewpoint - The AI Fund Huatai Medical Service Flexible Allocation Mixed A (001417) reported a profit of 779 million yuan in Q2 2025, with a weighted average profit per fund share of 0.317 yuan, and a net asset value growth rate of 21.05% during the reporting period [2] Fund Performance - As of July 18, the fund's net asset value growth rate over the past three months was 32.35%, ranking 51 out of 138 comparable funds; over the past six months, it was 66.01%, ranking 24 out of 138; over the past year, it was 59.85%, ranking 29 out of 133; and over the past three years, it was 15.90%, ranking 32 out of 107 [3] - The fund's Sharpe ratio over the past three years was 0.1999, ranking 29 out of 105 comparable funds [8] - The maximum drawdown over the past three years was 39.57%, ranking 54 out of 106 comparable funds, with the largest single-quarter drawdown occurring in Q3 2022 at 25.67% [10] Fund Holdings and Strategy - As of June 30, the fund maintained an average stock position of 88.04% over the past three years, compared to the industry average of 86.95% [13] - The fund had a high concentration of holdings, with the top ten positions including Heng Rui Medicine, Ke Lun Pharmaceutical, Hai Si Ke, Bai Li Tian Heng, Xin Nuo Wei, Ze Jing Pharmaceutical, Xin Li Tai, Re Jing Biological, Yi Fang Biological, and Nuo Cheng Jian Hua as of Q2 2025 [19] - The fund manager indicated a focus on innovative pharmaceutical companies with global competitiveness and growth potential, as well as leading medical device companies with low import substitution rates and high barriers to entry, anticipating continued resilience and technological attributes in the pharmaceutical industry over the next 2-3 years [2]
汇添富医疗服务灵活配置混合A：2025年第二季度利润7.79亿元 净值增长率21.05%
Sou Hu Cai Jing·2025-07-21 10:19